Our experienced board provides strong oversight and governance
Mr Robert W. Duggan has served as Summit’s Chief Executive Officer since April 2020 and a member of the Board of Directors since December 2019. He is a serial US based entrepreneur who has built several successful companies across different industries, including biotechnology. Mr Duggan is currently the Chief Executive Officer of Duggan Investment Inc., a private US investment firm. Mr Duggan has served on the boards of a number of US public and private companies and he is currently chairman of the board of the Nasdaq listed company, Pulse Biosciences, Inc. He was previously a substantial shareholder in and the Chairman of the Board and Chief Executive Officer of Pharmacyclics, Inc., which was sold to AbbVie Inc., in 2015. Previously, he was the Chairman of the Board and Chief Executive Officer of Computer Motion, Inc., which later merged with Intuitive Surgical, Inc.
Mr. Erdtmann has over 25 years of experience in the investment banking and the financial industries. He currently is a Portfolio Manager and General Partner at Point Sur Investors, a biotech focused investment fund. He also serves as President and co-founder of Biomea Health, a precision oncology company creating new generations of molecular scaffolds of targeting genetically defined diseases. Prior to Biomea Health, Mr. Erdtmann was 8 years at Pharmacyclics, Inc. (NASDAQ: PCYC) and oversaw a broad range of departments while helping to grow the company from 47-634 employees. He began leading the Finance Department and managed all Accounting, SEC Reporting, Audits and Investor Relations. He also built up and ran IT, HR, Legal, Facilities and Events for the company. Later, as the Executive Vice President of Corporate Affairs, he assumed additional responsibilities for Corporate Communications. Mr. Erdtmann actively participated in the final execution of key corporate milestones for Pharmacyclics, among them the Collaboration Agreement with J&J in 2011 (value $1.0 Billion) and the merger agreement with AbbVie in 2015 (value $21 Billion). Mr. Erdtmann served on the board of PolarityTE (NASDAQ PTE), a regenerative medicine company, where he was its Audit Committee Chair until March 2020. Mr. Erdtmann began his career at Commerzbank in Germany, where he was an investment banker and portfolio manager for large institutional accounts. He earned the Diplom Kaufmann degree with honors in finance and banking from the Westfaelische Wilhelms Universitaet of Muenster, Germany, the equivalent to a US Master of Business Administration degree.
Ms. Mahatme has over 30 years of experience in corporate law and financing in a diverse range of companies from start-ups to Fortune 500 companies, including those in the healthcare and biotechnology sector. She is the Founder and Managing Partner of Mahatme Bitterman PLLC, where she focuses on US and international clients in the healthcare/biotechnology, technology and real estate sectors. Previously, Ms. Mahatme served as Counsel at Gibson, Dunn & Crutcher and Counsel and Associate at Pillsbury Winthrop Shaw Pittman LLP. Ms. Mahatme serves on the board of Lakota Children’s Enrichment and was a past board member of the Board of Education, Lake Placid Central School District and Greenacres Association. She received her Bachelor of Commerce (accounting, business, and economics) from Brihan Maharashtra College of Commerce, University of Poona, her Bachelor of Laws (general) from ILS Law School, University of Poona, Master of Laws (general law) from the University of Cambridge and Master of Laws (corporate law) from New York University.
Mr Manmeet Soni has extensive experience in transitioning biotechnology companies from development stage through commercialisation and globalisation. He is currently the Chief Financial Officer and Executive Vice President of Reata Pharmaceuticals, Inc. where he is responsible for overall global functions of finance, tax, treasury, internal audit, information technology, investor relations, corporate communication and strategy functions. He has served as the Chief Financial Officer of several publicly-listed life science companies, including Pharmacyclics, Inc., where he played a vital role in the acquisition by Abbvie, Inc. for $21 billion in 2015, Ariad Pharmaceuticals Inc., where he played a major role in the acquisition by Takeda Inc. for $5.1 billion in 2017, and Alnylam Pharmaceuticals, Inc., where he raised over $2.5 billion in cash. Mr Soni currently serves on the board of Arena Pharmaceuticals, Inc. and Pulse Biosciences, Inc. He is a certified public accountant and chartered accountant from India and received his Bachelor of Commerce from Hansraj College, Delhi University, India.
Dr Ventzislav Stefanov joined our company in December of 2019 as Non-Executive Director and took an executive position in April 2020. Previously he was independent consultant providing advice, including to Duggan Investments Inc, on the therapeutic and commercial prospects of marketed and investigational antibiotics. In his previous tenures, Dr Stefanov held commercial and marketing positions with Bayer, Merck Sharp & Dohme, AstraZeneca and Eli Lilly. He had been involved in launching and marketing across Europe several classes of antibiotics including quinolones, carbapenems, cephalosporins and vancomycin. Dr Stefanov received his MD degree from the Medical University in Sofia, Bulgaria.